Chimeric IgA antibodies for lymphoma therapy

2001 ◽  
Vol 37 ◽  
pp. S51
Author(s):  
M. Dechant ◽  
G. Vidarsson ◽  
B. Stockmeyer ◽  
R. Repp ◽  
M. Glennie ◽  
...  
Keyword(s):  
Iga Antibodies ◽  
Lymphoma Therapy

The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

2019 ◽  
Vol 18 (28) ◽  
pp. 2380-2394 ◽  
Author(s):  
Na Liu ◽  
Rongtong Zhao ◽  
Yue Ma ◽  
Dongyuan Wang ◽  
Chen Yan ◽  
...  
Keyword(s):  
Drug Design ◽  
Rapid Development ◽  
Epigenetic Changes ◽  
Disease Treatment ◽  
Nucleosome Remodeling ◽  
Epigenetic Modifiers ◽  
The Us ◽  
Targeted Drug ◽  
Heritable Change ◽  
Lymphoma Therapy

Epigenetics process is the heritable change in gene function that does not involve changes in the DNA sequence. Until now, several types of epigenetic mechanisms have been characterized, including DNA methylation, histone modification (acetylation, methylation, etc.), nucleosome remodeling, and noncoding RNAs. With the biological investigations of these modifiers, some of them are identified as promoters in the process of various diseases, such as cancer, cardiovascular disease and virus infection. Epigenetic changes may serve as potential “first hits” for tumorigenesis. Hence, targeting epigenetic modifiers is being considered as a promising way for disease treatment. To date, six agents in two epigenetic target classes (DNMT and HDAC) have been approved by the US Food and Drug Administration (FDA). Most of these drugs are applied in leukemia, lymphoma therapy, or are combined with other drugs for the treatment of solid tumor. Due to the rapid development of epigenetics and epigenetics targeted drugs, it is becoming an emerging area in targeted drug design.

IgA Antibodies in the Vaginal Secretion after Vaccination with SolcoTrichovac

1983 ◽  
Vol 23 (2) ◽  
pp. 46-49 ◽  
Author(s):  
R. Milovanović ◽  
R. Grčić ◽  
L. Stojković
Keyword(s):  
Vaginal Secretion ◽  
Iga Antibodies

scholarly journals Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy

2020 ◽  
Author(s):  
Senlian Hong ◽  
Chenhua Yu ◽  
Peng Wang ◽  
Yujie Shi ◽  
Weiqian Cao ◽  
...  
Keyword(s):  
B Cell ◽  
Nk Cells ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphoma Therapy

scholarly journals Biomimetic nanotherapy: core–shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Qiangqiang Zhao ◽  
Duanfeng Jiang ◽  
Xiaoying Sun ◽  
Qiuyu Mo ◽  
Shaobin Chen ◽  
...  
Keyword(s):  
Mesoporous Silica Nanoparticles ◽  
Treatment Options ◽  
Inflammatory Factors ◽  
Main Method ◽  
Tnf Α ◽  
Good Biocompatibility ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
New Treatment ◽  
Lymphoma Therapy

Abstract Background Non-Hodgkin’s lymphoma (NHL) is a malignant disease of lymphoid tissue. At present, chemotherapy is still the main method for the treatment of NHL. R-CHOP can significantly improve the survival rate of patients. Unfortunately, DOX is the main cytotoxic drug in R-CHOP and it can lead to adverse reactions. Therefore, it is particularly important to uncover new treatment options for NHL. Results In this study, a novel anti-tumor nanoparticle complex Nm@MSNs-DOX/SM was designed and constructed in this study. Mesoporous silica nanoparticles (MSNs) loaded with Doxorubicin (DOX) and anti-inflammatory drugs Shanzhiside methylester (SM) were used as the core of nanoparticles. Neutrophil membrane (Nm) can be coated with multiple nanonuclei as a shell. DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-α and IL-1β. Consequently, the tumor microenvironment (TME) was reshaped, and the anti-tumor effect of DOX was amplified. Besides, Nm has good biocompatibility and can enhance the EPR effect of Nm@MSNs-DOX/SM and increase the effect of active targeting tumors. Conclusions This suggests that the Nm-modified drug delivery system Nm@MSNs-DOX/SM is a promising targeted chemotherapy and anti-inflammatory therapy nanocomplex, and may be employed as a specific and efficient anti-Lymphoma therapy.

scholarly journals Antibody in Middle Ear Fluid of Children Originates Predominantly from Sera and Nasopharyngeal Secretions

2012 ◽  
Vol 19 (10) ◽  
pp. 1593-1596 ◽  
Author(s):  
Ravinder Kaur ◽  
Thomas Kim ◽  
Janet R. Casey ◽  
Michael E. Pichichero
Keyword(s):  
Middle Ear ◽  
Acute Otitis Media ◽  
Secretory Iga ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Two Dimensional Gel Electrophoresis ◽  
Middle Ear Fluid ◽  
Iga Antibodies ◽  
Iga Antibody ◽  
Entire Array

ABSTRACTThe human middle ear is devoid of any immunocompetent cells in normal mucosa. We sought to determine the source of antibody present in the middle ear of children. Total IgG, IgA, and secretory IgA antibodies were determined by enzyme-linked immunosorbent assay from the nasopharyngeal, middle ear, and serum samples of children with acute otitis media. The two-dimensional gel electrophoresis pattern of the entire array of IgA antibodies in the nasal wash (NW) and middle ear fluid (MEF) was compared from the MEF and NW samples using isoelectric focusing and Western blotting. The total IgG and IgA antibodies in the MEF and NW samples of 137 children were compared. The ratio of IgG to IgA in the MEF was significantly different (P< 0.008) compared to NW because IgA levels were higher and IgG levels lower in NW. The IgG/IgA ratio of MEF resembled serum consistent with transudation to the MEF. Small amounts of secretory IgA were detected in MEF but the electrophoresis patterns of the entire array of IgA antibodies in the MEF and NW were virtually identical in each child evaluated; thus, IgA in MEF derived predominantly from serum and the nasopharynx by reflux via the Eustachian tube. The IgG/IgA antibody levels in the MEF and the same composition of IgA antibody in the MEF and NW identifies the predominant source of antibody in the MEF as a transudate of serum combined with nasal secretions refluxed from the nasopharynx in children.

scholarly journals Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ariel Munitz ◽  
L. Edry-Botzer ◽  
M. Itan ◽  
R. Tur-Kaspa ◽  
D. Dicker ◽  
...  
Keyword(s):  
Nucleocapsid Protein ◽  
Neutralizing Antibodies ◽  
Host Response ◽  
Humoral Response ◽  
Rapid Onset ◽  
Response Analysis ◽  
Receptor Binding Domain ◽  
Igg Antibodies ◽  
Viral Receptor ◽  
Iga Antibodies

AbstractDespite ongoing efforts to characterize the host response toward SARS-CoV-2, a major gap in our knowledge still exists regarding the magnitude and duration of the humoral response. Analysis of the antibody response in mild versus moderate/severe patients, using our new developed quantitative electrochemiluminescent assay for detecting IgM/IgA/IgG antibodies toward SARS-CoV-2 antigens, revealed a rapid onset of IgG/IgA antibodies, specifically in moderate/severe patients. IgM antibodies against the viral receptor binding domain, but not against nucleocapsid protein, were detected at early stages of the disease. Furthermore, we observed a marked reduction in IgM/IgA antibodies over-time. Adapting our assay for ACE2 binding-competition, demonstrated that the presence of potentially neutralizing antibodies is corelated with IgG/IgA. Finally, analysis of the cytokine profile in COVID-19 patients revealed unique correlation of an IL-12p70/IL33 and IgG seroconversion, which correlated with disease severity. In summary, our comprehensive analysis has major implications on the understanding and monitoring of SARS-CoV-2 infections.

scholarly journals Presence of anti-Toxoplasma antibodies in humans and their cats in the urban zone of Guadalajara

1999 ◽  
Vol 32 (5) ◽  
pp. 483-488 ◽  
Author(s):  
María de la Luz Galván Ramírez ◽  
Guillermo Sánchez Vargas ◽  
Marcos Vielma Sandoval ◽  
Juan Luis Soto Mancilla
Keyword(s):  
Risk Factors ◽  
Toxoplasma Gondii ◽  
Immunosorbent Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Toxoplasma Infection ◽  
Urban Zone ◽  
Lack Of Control ◽  
Iga Antibodies

Cats are the definitive hosts of Toxoplasma gondii. Infected cats excrete oocysts in their feces, infecting humans and other animals. The objective of the present study was to determine the presence of anti-Toxoplasma antibodies in cat owners and their pets, and determine if there was a relationship between Toxoplasma infection and humans who live with infected cats. IgG anti-Toxoplasma antibodies in sera of 59 cat owners were determined by enzyme-linked immunosorbent assay (ELISA), in 24 sera from their cats, IgG, IgM, and IgA antibodies were found using Burney's ELISA. Thirty-eight (64%) of 59 cat owners were positive to IgG anti-Toxoplasma. Seropositivity for cats was 70.8% IgG, 8.3% IgM, and 62.5% IgA. Cohabitation with cats infected by T. gondii, feeding with leftovers or raw viscera, and lack of control over how their feces were handled are risk factors conducive for humans to become infected by T. gondii.

Sign in / Sign up

Export Citation Format

Share Document